12 West Capital Management’s Pacific Biosciences PACB Stock Holding History

12 West Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,925,000	Closed	-$11.2M	–	23
2022 Q3	$11.2M	Hold	1,925,000	–	–	0.99%	18
2022 Q2	$8.51M	Buy	+1,925,000	New	+$11.7M	0.73%	19

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

12 West Capital Management's PACB Position: Q4 2022 in Review

12 West Capital Management sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 1,925,000 shares — an estimated $11.2M sold.

12 West Capital Management first reported a position in PACB in Q2 2022 and held it in 2 quarters. The position peaked at $11.2M in Q3 2022. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

12 West Capital Management reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
12 West Capital Management sold 1,925,000 Pacific Biosciences shares in Q4 2022, an estimated $11.2M.
12 West Capital Management first reported a position in Pacific Biosciences in Q2 2022 and held it in 2 quarters.
12 West Capital Management's Pacific Biosciences position peaked at $11.2M in Q3 2022.
236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on 12 West Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.